Anti-Cancer Drug Design

Editorial. Review. Molecular approaches to achieving control of gene expression by drug intervention at the transcriptional level
pp. 1-9(9)
Authors: Zewail-Foote M.; Hurley L.

The role of base excision repair in the repair of DNA adducts formed by a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size
pp. 11-18(8)
Authors: Brooks N.; McHugh P.; Lee M.; Hartley J.

Bis-benzimidazole anticancer agents: targeting human tumour helicases
pp. 19-36(18)
Authors: Soderlind K-J.; Gorodetsky B.; Singh A.; Bachur N.; Miller G.; Lown J.

5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4- carboxamide (DACA): DNA binding and patterns of cytotoxicity
pp. 37-45(9)
Authors: Spicer J.; Finlay G.; Baguley B.; Velea L.; Graves D.; Denny W.

Relationship between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives
pp. 47-60(14)
Authors: Bailly C.; Dassonneville L.; Carrasco C.; Lucas D.; Kumar A.; Boykin D.; Wilson W.

Polybenzamide mustards: structure-activity relationship for DNA sequence-specific alkylation
pp. 61-70(10)
Authors: Turner P.; Ferguson L.; Denny W.

PNU 157977: a new potent antitumour agent exhibiting low in vivo toxicity in mice injected with L1210 leukaemia cells
pp. 71-76(6)
Authors: Baraldi P.; Balboni G.; Romagnoli R.; Spalluto G.; Cozzi P.; Geroni C.; Mongelli N.; Rutigliano C.; Bianchi N.; Gambari R.

Comparison of the patterns of DNA alkylation by phenol and amino seco-CBI-TMI compounds: use of a PCR method for the facile preparation of single end-labelled double-stranded DNA
pp. 77-84(8)
Authors: Gieseg M.; Matejovic J.; Denny W.

Announcement
pp. 85-85(1)
Author: Anon